Abatacept: A review of a new biologic agent for refractory rheumatoid arthritis for dermatologists

References

• Abatacept (Orencia) for rheumatoid arthritis. Med Lett Drugs Ther 2006; 48: 17–18
   Google Scholar
• Drugs for rheumatoid arthritis. Treat Guidel Med Lett 2005; 3: 83–90
   Google Scholar
• Teng G. G., Turkiewicz A. M., Moreland L. W. Abatacept: a costimulatory inhibitor for treatment of rheumatoid arthritis. Expert Opin Biol Ther 2005; 5: 1245–54
   PubMed Web of Science ®Google Scholar
• Kremer J. M. Selective costimulation modulators: a novel approach for the treatment of rheumatoid arthritis. J Clin Rheumatol 2005; 11 suppl 3: S55
   Google Scholar
• Cohen SB. Recent advances in biologic therapies. [Accessed 16 April 2006.] URL: http://www.medscape.com/viewarticle/520056
   Google Scholar
• Zashin SJ. Orencia (Abatacept) – Drug information – Drug side effects / Orencia vs TNF antagonists – What's the difference? [Accessed 16 April 2006.] URLs: http://arthritis.about.com/od/abatacept/, http://arthritis.about.com/od/abatacept/f/orencia.htm
   Google Scholar
• Hervey P. S., Keam S. J. Abatacept. BioDrugs 2006; 20: 53–61
   Google Scholar
• Westhovens R., Cole J. C., Li T., et al. Improved health‐related quality of life for rheumatoid arthritis patients treated with abatacept who have inadequate response to anti‐TNF therapy in a double‐blind, placebo‐controlled, multicentre randomized clinical trial. Rheumatology (Oxford) 2006, epublication
   Google Scholar
• Moreland L. W., Alten R., Van den Bosch F., et al. Costimulatory blockade in patients with rheumatoid arthritis: a pilot, dose‐finding, double‐blind, placebo‐controlled clinical trial evaluating CTLA‐4Ig and LEA29Y eighty‐five days after the first infusion. Arthritis Rheum 2002; 46: 1470–9
   PubMed Web of Science ®Google Scholar
• Kremer J. M., Dougados M., Emery P., et al. Treatment of rheumatoid arthritis with the selective costimulation modulator abatacept: twelve‐month results of a phase IIb, double‐blind, randomized, placebo‐controlled trial. Arthritis Rheum 2005; 52: 2263–71
   PubMed Web of Science ®Google Scholar
• Genovese M. C., Becker J. C., Schiff M., et al. Abatacept for rheumatoid arthritis refractory to tumor necrosis factor alpha inhibition. N Engl J Med 2005; 353: 1114–23
   PubMed Web of Science ®Google Scholar
• Raffeiner B., Dejaco C., Duftner C., et al. Between adaptive and innate immunity: TLR4‐mediated perforin production by CD28null T‐helper cells in ankylosing spondylitis. Arthritis Res Ther 2005; 7((6))R1412–20
   Google Scholar
• Horneff G. Importance of the new biologicals and cytokine antagonists in the treatment of juvenile idiopathic arthritis (JIA). Z Rheumatol 2005; 64: 317–26
   Google Scholar
• Abrams J. R., Lebwohl M. G., Guzzo C. A., et al. CTLA4Ig‐mediated blockade of T‐cell costimulation in patients with psoriasis vulgaris. J Clin Invest 1999; 103: 1243–52
   PubMed Web of Science ®Google Scholar
• Abrams J. R., Kelley S. L., Hayes E., et al. Blockade of T lymphocyte costimulation with cytotoxic T lymphocyte‐associated antigen 4‐immunoglobulin (CTLA4Ig) reverses the cellular pathology of psoriatic plaques, including the activation of keratinocytes, dendritic cells, and endothelial cells. J Exp Med 2000; 192: 681–94
   PubMed Web of Science ®Google Scholar
• Dall'Era M., Davis J. CTLA4Ig: a novel inhibitor of costimulation. Lupus 2004; 13: 372–6
   PubMed Web of Science ®Google Scholar
• Davenport C. M., McAdams H. A., Kou J., et al. Inhibition of pro‐inflammatory cytokine generation by CTLA4‐Ig in the skin and colon of mice adoptively transplanted with CD45RBhi CD4+ T cells correlates with suppression of psoriasis and colitis. Int Immunopharmacol 2002; 2: 653–72
   Google Scholar
• Mitra R. S., Judge T. A., Nestle F. O., Turka L. A., Nickoloff B. J. Psoriatic skin‐derived dendritic cell function is inhibited by exogenous IL‐10. J Immunol 1995; 154: 2668–77
   PubMed Web of Science ®Google Scholar
• De Rie M. A., Cairo I., Van Lier R. A., Bos J. D. Expression of the T‐cell activation antigens CD27 and CD28 in normal and psoriatic skin. Clin Exp Dermatol 1996; 21: 104–11
   Google Scholar
• Najafian N., Sayegh M. H. CTLA4‐Ig: a novel immunosuppressive agent. Expert Opin Investig Drugs 2000; 9: 2147–57
   PubMed Web of Science ®Google Scholar
• Wechsler A. S., Gordon M. C., Dendorfer U., LeClair K. P. Induction of IL‐8 expression in T cells uses the CD28 costimulatory pathway. J Immunol 1994; 153: 2515–23
   PubMedGoogle Scholar
• Kremer J. M., Genant H. K., Moreland L. W., Russell A. S., Emery P., Abud‐Mendoza C., et al. Effects of abatacept in patients with methotrexate‐resistant active rheumatoid arthritis: a randomized trial. Ann Intern Med 2006; 144: 865–76
   PubMed Web of Science ®Google Scholar